Psychedelic Psychiatry's Brave New World

Cell. 2020 Apr 2;181(1):24-28. doi: 10.1016/j.cell.2020.03.020.


After a legally mandated, decades-long global arrest of research on psychedelic drugs, investigation of psychedelics in the context of psychiatric disorders is yielding exciting results. Outcomes of neuroscience and clinical research into 5-Hydroxytryptamine 2A (5-HT2A) receptor agonists, such as psilocybin, show promise for addressing a range of serious disorders, including depression and addiction.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Hallucinogens / therapeutic use*
  • Humans
  • Mental Disorders / drug therapy*
  • Neuropharmacology
  • Psilocybin / therapeutic use*
  • Psychiatry
  • Serotonin 5-HT2 Receptor Agonists / therapeutic use*


  • Hallucinogens
  • Serotonin 5-HT2 Receptor Agonists
  • Psilocybin